Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Purpose of review To highlight recent results in targeting mRNA translation and discuss the results and prospects of translation inhibitors in cancer therapy. Recent findings Until recently, inhibitors of mRNA translation have been thought to likely lack a therapeutic window. In 2012, the Food and Drug Administration (FDA) approved omacetaxine mepesuccinate (homoharringtonine) for the treatment of adults with chronic myelogenous leukemia (CML) who are resistant to at least two tyrosine kinase inhibitors. Since then, a few drugs, notably tomivosertib (eFT-508), selinexor (KPT-330), and ribavirin, have entered clinical trials. These drugs are known to inhibit mRNA translation. More recently, a number of interesting studies report that discrete subsets of proteins in cancer cells may be selectively targeted at the translation step, through inhibiting signals such as phospho-4E-BP1, eIF4A, and eIF4E. Promising therapies using these strategies have demonstrated potent anti-tumor activity in preclinical cancer models. The growing number of translation inhibitors with diverse mechanisms, coupled with emerging insights into translational regulation of different cancer-promoting genes, suggests a bright new horizon for the field of therapeutic targeting of mRNA translation in cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [15]
Citations
Cites
1 retracted
Garg, M., Kanojia, D., Mayakonda, A., Ganesan, T. S., Sadhanandhan, B., Suresh, S., Sneha, S., Nagare, R. P., SAID, J. W., Doan, N., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10325-x · Cited by 48
RetractedmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Gingras, A.-C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,343
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093
Johnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0985 · Cited by 975
Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them
Leppek, K., Das, R., & Barna, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.103 · Cited by 949
Green, T. M., Young, K. H., Visco, C., Xu-Monette, Z. Y., Orazi, A., Go, R. S., Nielsen, O., Gadeberg, O. V., Mourits-Andersen, T., Frederiksen, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4342 · Cited by 686
Hu, S., Xu-Monette, Z. Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W.-M., Visco, C., Li, Y., Miranda, R. N., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460063 · Cited by 679
Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., Horsman, D. E., & Gascoyne, R. D. (2009) · Blood · doi:10.1182/blood-2009-05-220095 · Cited by 660
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Haghighat, A., Mader, S., Pause, A., & Sonenberg, N. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00257.x · Cited by 612
MYC, Metabolism, Cell Growth, and Tumorigenesis
Dang, C. V. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014217 · Cited by 602
Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Patmore, R., Roman, E., & Jack, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3947 · Cited by 552
Regulation of eIF-4E BP1 Phosphorylation by mTOR
Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K., Weng, Q.-P., Kasuga, M., Nishimoto, I., & Avruch, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26457 · Cited by 527
Ueda, T., Watanabe-Fukunaga, R., Fukuyama, H., Nagata, S., & Fukunaga, R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6539-6549.2004 · Cited by 507
The mammalian ribo-interactome reveals ribosome functional diversity and heterogeneity
Simsek, D., Tiu, G. C., Flynn, R. A., Byeon, G. W., Leppek, K., Xu, A. F., Chang, H. Y., & Barna, M. (2017) · Cell · doi:10.1016/j.cell.2017.05.022 · Cited by 439
Carrasco, D. R., Tonon, G., Huang, Y., Zhang, Y., Sinha, R., Feng, B., Stewart, J. P., Zhan, F., Khatry, D., Protopopova, M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.019 · Cited by 425
Ribosome Footprint Profiling of Translation throughout the Genome
Ingolia, N. T. (2016) · Cell · doi:10.1016/j.cell.2016.02.066 · Cited by 409
Differential Requirements for eIF4E Dose in Normal Development and Cancer
Truitt, M. L., Conn, C. S., Shi, Z., Pang, X., Tokuyasu, T., Coady, A. M., Seo, Y., Barna, M., & Ruggero, D. (2015) · Cell · doi:10.1016/j.cell.2015.05.049 · Cited by 368
Control of mammalian translation by mRNA structure near caps
Babendure, J. R., Babendure, J. L., Ding, J.-H., & Tsien, R. Y. (2006) · RNA · doi:10.1261/rna.2309906 · Cited by 339
Bordeleau, M.-E., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M. H., Wendel, H.-G., Brem, B., Greger, H., Lowe, S. W., Porco, J. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34753 · Cited by 332
Assouline, S., Culjkovic, B., Cocolakis, E., Rousseau, C., Beslu, N., Amri, A., Caplan, S., Leber, B., Roy, D.-C., Miller, W. H., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205153 · Cited by 314
Walker, B. A., Wardell, C. P., Murison, A., Boyle, E. M., Begum, D. B., Dahir, N. M., Proszek, P. Z., Melchor, L., Pawlyn, C., Kaiser, M. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms7997 · Cited by 313
Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor
Iwasaki, S., Floor, S. N., & Ingolia, N. T. (2016) · Nature · doi:10.1038/nature17978 · Cited by 313
Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005223 · Cited by 302
eIF4E is a central node of an RNA regulon that governs cellular proliferation
Culjkovic, B., Topisirovic, I., Skrabanek, L., Ruiz-Gutierrez, M., & Borden, K. L. B. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200607020 · Cited by 293
Chng, W.-J., Huang, G. F., Chung, T. H., Ng, S. B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P. L., & Fonseca, R. (2011) · Leukemia · doi:10.1038/leu.2011.53 · Cited by 270
Affer, M., Chesi, M., Chen, W. D., Keats, J. J., Demchenko, Y. N., Tamizhmani, K., Garbitt, V. M., Riggs, D. L., Brents, L. A., Roschke, A. V., et al. (2014) · Leukemia · doi:10.1038/leu.2014.70 · Cited by 268
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
Copie-Bergman, C., Cuillière-Dartigues, P., Baia, M., Briere, J., Delarue, R., Canioni, D., Salles, G., Parrens, M., Belhadj, K., Fabiani, B., et al. (2015) · Blood · doi:10.1182/blood-2015-05-647602 · Cited by 255
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., Allard, D., Martineau, S., Welsch, C., Agoussi, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0217-1 · Cited by 254
Inhibition of Eukaryotic Translation Initiation by the Marine Natural Product Pateamine A
Low, W.-K., Dang, Y., Schneider-Poetsch, T., Shi, Z., Choi, N. S., Merrick, W. C., Romo, D., & Liu, J. O. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.008 · Cited by 250
eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3′UTR
Culjkovic, B., Topisirovic, I., Skrabanek, L., Ruiz-Gutierrez, M., & Borden, K. L. B. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200501019 · Cited by 204
Silvestrol and Episilvestrol, Potential Anticancer Rocaglate Derivatives from Aglaia silvestris
Hwang, B. Y., Su, B.-N., Chai, H., Mi, Q., Kardono, L. B. S., Afriastini, J. J., Riswan, S., Santarsiero, B. D., Mesecar, A. D., Wild, R., et al. (2004) · The Journal of Organic Chemistry · doi:10.1021/jo040120f · Cited by 193
Heßmann, E., Schneider, G., Ellenrieder, V., & Siveke, J. T. (2015) · Oncogene · doi:10.1038/onc.2015.216 · Cited by 184
Pateamine: a potent cytotoxin from the New Zealand Marine sponge, mycale sp.
Northcote, P. T., Blunt, J. W., & Munro, M. H. G. (1991) · Tetrahedron Letters · doi:10.1016/0040-4039(91)80182-6 · Cited by 179
Reich, S. H., Sprengeler, P. A., Chiang, G. G., Appleman, J. R., Chen, J., Clarine, J., Eam, B., Ernst, J. T., Han, Q., Goel, V. K., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01795 · Cited by 175
Lucas, D. M., Edwards, R. B., Lozanski, G., West, D. A., Shin, J. D., Vargo, M. A., Davis, M. E., Rozewski, D. M., Johnson, A. J., Su, B.-N., et al. (2009) · Blood · doi:10.1182/blood-2008-09-175430 · Cited by 171
NESdb: a database of NES-containing CRM1 cargoes
Xu, D., Grishin, N. V., & Chook, Y. M. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-01-0045 · Cited by 170
Gounder, M. M., Zer, A., Tap, W. D., Salah, S., Dickson, M. A., Gupta, A. A., Keohan, M. L., Loong, H. H., D’Angelo, S. P., Baker, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6346 · Cited by 164
Atomic basis of CRM1-cargo recognition, release and inhibition
Fung, H. Y. J., & Chook, Y. M. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.03.002 · Cited by 161
Vogl, D. T., Dingli, D., Cornell, R. F., Huff, C. A., Jagannath, S., Bhutani, D., Zonder, J., Baz, R., Nooka, A., Richter, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5207 · Cited by 161
Inhibitors of nuclear transport
Jans, D. A., Martin, A. J., & Wagstaff, K. M. (2019) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2019.01.001 · Cited by 161
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia
Garzon, R., Savona, M. R., Baz, R., Andreeff, M., Gabrail, N. Y., Gutierrez, M. E., Savoie, L., Mau‐Sørensen, M., Wagner‐Johnston, N., Yee, K. W. L., et al. (2017) · Blood · doi:10.1182/blood-2016-11-750158 · Cited by 160
Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?
Borden, K. L. B., & Čuljković, B. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.496506 · Cited by 159
Mnk kinase pathway: Cellular functions and biological outcomes
Joshi, S. (2014) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v5.i3.321 · Cited by 159
Jin, J., Wang, J., Chen, F.-F., Wu, D., Hu, J., Zhou, J., Hu, J., Wang, J., Li, J., Huang, X., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70152-9 · Cited by 158
Schleger, C., Verbeke, C. S., Hildenbrand, R., Zentgraf, H., & Bleyl, U. (2002) · Modern Pathology · doi:10.1038/modpathol.3880547 · Cited by 153
Romo, D., Rzasa, R. M., Shea, H. A., Park, K., Langenhan, J. M., Sun, L., Akhiezer, A., & Liu, J. O. (1998) · Journal of the American Chemical Society · doi:10.1021/ja981846u · Cited by 151
Çağatay, T., & Chook, Y. M. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2018.01.006 · Cited by 147
Culjkovic-Kraljacic, B., Baguet, A., Volpon, L., Amri, A., & Borden, K. L. B. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.07.007 · Cited by 146
Inhibiting cancer cell hallmark features through nuclear export inhibition
Sun, Q., Chen, X., Zhou, Q., Burstein, E., Yang, S., & Jia, D. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.10 · Cited by 140
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
Gandhi, U. H., Senapedis, W. T., Baloglu, E., Unger, T. J., Chari, A., Vogl, D. T., & Cornell, R. F. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.03.003 · Cited by 130
Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine
Hood, K. A., West, L. M., Northcote, P. T., Berridge, M. V., & Miller, J. H. (2001) · APOPTOSIS · doi:10.1023/a:1011340827558 · Cited by 118
Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding
Andresen, C., Helander, S., Lemak, A., Farès, C., Csizmok, V., Carlsson, J., Penn, L. Z., Forman-Kay, J. D., Arrowsmith, C. H., Lundström, P., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks263 · Cited by 117
Ribosome Profiling Reveals a Cell-Type-Specific Translational Landscape in Brain Tumors
Gonzalez, C., Sims, J. S., Hornstein, N., Mela, A., Garcia, F., Lei, L., Gass, D. A., Amendolara, B., Bruce, J. N., Canoll, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0084-14.2014 · Cited by 116
Kim, S.-Y., Hwang, B. Y., Su, B., Chai, H., Mi, Q., Kinghorn, A. D., Wild, R., & Swanson, S. M. (2007) · PubMed · Cited by 116
Deng, C., Lipstein, M. R., Scotto, L., Serrano, X. O. J., Mangone, M. A., Li, S., Vendôme, J., Hao, Y., Xu, X., Deng, S., et al. (2016) · Blood · doi:10.1182/blood-2016-08-731240 · Cited by 115
Self-citationThe past, present, and future of CRM1/XPO1 inhibitors
Wang, A. Y., & Liu, H. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.02.03 · Cited by 114
Lin, P.-Y., & Medeiros, L. J. (2007) · Haematologica · doi:10.3324/haematol.11263 · Cited by 112
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009
Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24601 · Cited by 111
Zhang, M., Wang, Z., Obazee, O., Jia, J., Childs, E. J., Hoskins, J., Figlioli, G., Mocci, E., Collins, I., Chung, C. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11041 · Cited by 110
Ranganathan, P., Kashyap, T., Yu, X., Meng, X., Lai, T.-H., McNeil, B., Bhatnagar, B., Shacham, S., Kauffman, M. G., Dorrance, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2885 · Cited by 108
Kuznetsov, G., Xu, Q., Rudolph-Owen, L., TenDyke, K., Liu, J., Towle, M., Zhao, N., Marsh, J., Agoulnik, S., Twine, N., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1026 · Cited by 105
Ghobrial, I. M., Siegel, D. S., Vij, R., Berdeja, J. G., Richardson, P. G., Neuwirth, R., Patel, C. G., Zohren, F., & Wolf, J. L. (2016) · American Journal of Hematology · doi:10.1002/ajh.24300 · Cited by 95
Romo, D., Choi, N. S., Li, S., Buchler, I. P., Shi, Z., & Liu, J. O. (2004) · Journal of the American Chemical Society · doi:10.1021/ja040065s · Cited by 85
Tujebajeva, R. M., Graifer, D. M., Karpova, G. G., & Ajtkhozhina, N. A. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)81546-7 · Cited by 85
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct forFLT3-ITD acute myeloid leukemia
Lam, S. S. Y., Ho, E. S. K., He, A. B.-L., Wong, W.-W., Cher, C. Y., Ng, N. K. L., Man, C., Gill, H., Cheung, A. M. S., Ip, H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3735 · Cited by 85
Gupta, S. V., Sass, E. J., Davis, M. E., Edwards, R. B., Lozanski, G., Heerema, N. A., Lehman, A., Zhang, X., Jarjoura, D., Byrd, J. C., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9276-7 · Cited by 81
KPT-330 has antitumour activity against non-small cell lung cancer
Sun, H., Hattori, N., Chien, W., Sun, Q., Sudo, M., E-Ling, G. L., Ding, L., Lim, S. L., Shacham, S., Kauffman, M. G., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.260 · Cited by 81
Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Wetzler, M., & Segal, D. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049778 · Cited by 81
Culjkovic‐Kraljacic, B., Argüello, M., Amri, A., Cormack, G., & Borden, K. L. B. (2011) · Leukemia · doi:10.1038/leu.2011.57 · Cited by 71
Manier, S., Huynh, D., Shen, Y. J., Zhou, J., Yusufzai, T., Salem, K. Z., Ebright, R. Y., Shi, J., Park, J., Glavey, S. V., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2668 · Cited by 70
Cencic, R., Carrier, M., Trnkus, A., Porco, J. A. J., Minden, M. D., & Pelletier, J. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.07.043 · Cited by 69
Therapeutic Potential of the Translation Inhibitor Silvestrol in Hepatocellular Cancer
Kogure, T., Kinghorn, A. D., Yan, I., Bolon, B., Lucas, D. M., Grever, M. R., & Patel, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076136 · Cited by 68
Chen, R., Dawson, D. W., Pan, S., Ottenhof, N. A., de Wilde, R. F., Wolfgang, C. L., May, D. H., Crispin, D. A., Lai, L. A., Lay, A. R., et al. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2014.128 · Cited by 59
Yun, S., Vincelette, N. D., Knorr, K. L. B., Almada, L. L., Schneider, P. A., Peterson, K. L., Flatten, K. S., Dai, H., Pratz, K. W., Hess, A. D., et al. (2016) · Blood · doi:10.1182/blood-2015-02-629485 · Cited by 58
Casein Kinase 1ϵ Promotes Cell Proliferation by Regulating mRNA Translation
Shin, S., Wolgamott, L., Roux, P. P., & Yoon, S.-O. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1175 · Cited by 57
Zhang, W., Ly, C., Ishizawa, J., Mu, H., Ruvolo, V. R., Shacham, S., Daver, N. G., & Andreeff, M. (2018) · Haematologica · doi:10.3324/haematol.2017.185082 · Cited by 55
Yang, J., Bill, M. A., Young, G. S., Perle, K. L., Landesman, Y., Shacham, S., Kauffman, M. G., Senapedis, W. T., Kashyap, T., Saint‐Martin, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102983 · Cited by 53
Kosaka, T., Nagamatsu, G., Saito, S., Oya, M., Suda, T., & Horimoto, K. (2013) · Cancer Science · doi:10.1111/cas.12183 · Cited by 53
Silvestrol induces early autophagy and apoptosis in human melanoma cells
Chen, W.-L., Li, P., Kinghorn, A. D., Swanson, S. M., & Burdette, J. E. (2016) · BMC Cancer · doi:10.1186/s12885-015-1988-0 · Cited by 52
Low, W., Li, J., Zhu, M., Kommaraju, S. S., Shah-Mittal, J., Hull, K., Liu, J. O., & Romo, D. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.11.046 · Cited by 50
Dunn, L. A., Fury, M. G., Sherman, E. J., Ho, A. L., Katabi, N., Haque, S. S., & Pfister, D. G. (2017) · Head & Neck · doi:10.1002/hed.24938 · Cited by 46
Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia
Urtishak, K. A., Wang, L.-S., Čuljković, B., Davenport, J. W., Porazzi, P., Vincent, T. L., Teachey, D. T., Tasian, S. K., Moore, J. S., Seif, A. E., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0567-7 · Cited by 46
Mnk kinases in cytokine signaling and regulation of cytokine responses
Joshi, S., & Platanias, L. C. (2015) · Biomolecular Concepts · doi:10.1515/bmc-2011-2000 · Cited by 44
Korneeva, N. L., Song, A., Gram, H., Edens, M. A., & Rhoads, R. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.694190 · Cited by 43
Riner, A. N., Chan‐Tack, K. M., & Murray, J. S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.2014 · Cited by 38
Khoury, H. J., Cortes, J. E., Baccarani, M., Wetzler, M., Masszi, T., Digumarti, R., Craig, A., Benichou, A., & Akard, L. P. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.889826 · Cited by 37
Mnk kinases in cytokine signaling and regulation of cytokine responses
Joshi, S., & Platanias, L. C. (2012) · Biomolecular Concepts · doi:10.1515/bmc-2011-1057 · Cited by 37
Demosthenous, C., Han, J., Stenson, M. J., Maurer, M. J., Wellik, L. E., Link, B. K., Hege, K. M., Doǧan, A., Sotomayor, E. M., Witzig, T. E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3378 · Cited by 35
Low, W., Dang, Y., Schneider‐Poetsch, T., Shi, Z., Choi, N. S., Rzasa, R. M., Shea, H. A., Li, S., Park, K., Ma, G., et al. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)31014-8 · Cited by 34
Oblinger, J. L., Burns, S. S., Huang, J., Li, P., Ren, Y., Shen, R. Z., Kinghorn, A. D., Welling, D. B., & Chang, L. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.06.015 · Cited by 27
Liu, J., Mi, Y., Fu, M., Yu, W., Wang, Y., Lin, D., Bian, S., & Wang, J. (2009) · American Journal of Hematology · doi:10.1002/ajh.21441 · Cited by 23
Zhang, C., Yang, L., Geng, Y., An, F., Xia, Y., Guo, C., Luo, J., Zhang, L., Guo, Q., & Kong, L. (2016) · Oncotarget · doi:10.18632/oncotarget.8538 · Cited by 23
Kuo, S., Hsu, C., Chen, L., Lu, Y., Lin, C.-H., Yeh, P.-Y., Jeng, H., Gao, M., Yeh, K., & Cheng, A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.003 · Cited by 22
Selective inhibition of the polypeptide chain elongation in eukaryotic cells
Tujebajeva, R. M., Graifer, D. M., Matasova, N. B., Fedorova, O. S., Odintsov, V. B., Ajtkhozhina, N. A., & Karpova, G. G. (1992) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(92)90484-h · Cited by 21
Pharmacological targeting of eIF4E in primary CLL lymphocytes
Marignac, V. L. M., Shawi, M., Carpio, E. P., Wang, X., Panasci, L., Miller, W. H., Pettersson, F., & Aloyz, R. S. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.43 · Cited by 21
Chen, R., Zhu, M., Chaudhari, R. R., Robles, O., Chen, Y., Skillern, W., Qin, Q., Wierda, W. G., Zhang, S., Hull, K. G., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0364-x · Cited by 20
Daker, M., YEO, J.-T., Bakar, N., RAHMAN, A. S. A. A. A., Ahmad, M., Yeo, T. C., & Khoo, A. S. B. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3201 · Cited by 14
Kim, Y. R., Pal, I., Lipstein, M. R., Zhu, M., Kenneth, H., Romo, D., O’Connor, O. A., & Deng, C. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.4111.4111 · Cited by 1
Self-citation
Cited by
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Protein synthesis control in cancer: selectivity and therapeutic targeting
Kovalski, J. R., Kuzuoğlu‐Öztürk, D., & Ruggero, D. (2022) · The EMBO Journal · doi:10.15252/embj.2021109823 · Cited by 133
PD-L1 regulation revisited: impact on immunotherapeutic strategies
Lucibello, G., Mograbi, B., Milano, G. A., Hofman, P. M., & Brest, P. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.005 · Cited by 57
RNA-binding proteins in cancer drug discovery
Bertoldo, J. B., Müller, S., & Hüttelmaier, S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103580 · Cited by 54
Non-coding RNA delivery for bone tissue engineering: Progress, challenges, and potential solutions
Guan, S., Zhang, Z., & Wu, J. (2022) · iScience · doi:10.1016/j.isci.2022.104807 · Cited by 41
Metadata
- Authors
- Pal, I., Safari, M., Jovanovic, M., Bates, S. E., & Deng, C.
- Affiliations
- Columbia University Irving Medical Center (US)
- Corresponding author
- Deng, Changchun
- Venue
- Current Hematologic Malignancy Reports
- Published
- 2019-06-24
- Volume
- 14
- Issue
- 4
- Pages
- 219-227
- ISSN
- 1558-8211 (ISSN-L)
- 1558-822X
- OpenAlex
- W2951271467
- Cited by
- 46
- References
- 102
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 6 · 2022: 12 · 2021: 13 · 2020: 7 · 2019: 1
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Current Hematologic Malignancy Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- mRNA translation inhibition, translation inhibitors, cancer therapy, homoharringtonine, omacetaxine mepesuccinate, chronic myeloid leukemia, selinexor, ribavirin, 4E-BP1, eIF4A, eIF4E, translational regulation, tyrosine kinase inhibitor resistance
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, RNA, Messenger, Protein Biosynthesis, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.